| Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study NA Kennedy, GA Heap, HD Green, B Hamilton, C Bewshea, GJ Walker, ... The lancet Gastroenterology & hepatology 4 (5), 341-353, 2019 | 574 | 2019 |
| Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study CDR Murray, NM Martin, M Patterson, SA Taylor, MA Ghatei, MA Kamm, ... Gut 54 (12), 1693-1698, 2005 | 400 | 2005 |
| HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease A Sazonovs, NA Kennedy, L Moutsianas, GA Heap, DL Rice, M Reppell, ... Gastroenterology 158 (1), 189-199, 2020 | 312 | 2020 |
| British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic NA Kennedy, GR Jones, CA Lamb, R Appleby, I Arnott, RM Beattie, ... Gut 69 (6), 984-990, 2020 | 291 | 2020 |
| Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome CDR Murray, J Flynn, L Ratcliffe, MR Jacyna, MA Kamm, AV Emmanuel Gastroenterology 127 (6), 1695-1703, 2004 | 262 | 2004 |
| Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a … SA Taylor, S Mallett, G Bhatnagar, R Baldwin-Cleland, S Bloom, A Gupta, ... The lancet Gastroenterology & hepatology 3 (8), 548-558, 2018 | 201 | 2018 |
| Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab NA Kennedy, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin, ... Gut 70 (5), 865-875, 2021 | 178 | 2021 |
| Gastrointestinal manifestations of systemic sclerosis AB Shreiner, C Murray, C Denton, D Khanna Journal of scleroderma and related disorders 1 (3), 247-256, 2016 | 150 | 2016 |
| A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis PM Irving, T Iqbal, C Nwokolo, S Subramanian, S Bloom, N Prasad, A Hart, ... Inflammatory bowel diseases 24 (4), 714-724, 2018 | 144 | 2018 |
| Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis NA Kennedy, B Warner, EL Johnston, L Flanders, P Hendy, NS Ding, ... Alimentary pharmacology & therapeutics 43 (8), 910-923, 2016 | 119 | 2016 |
| Ghrelin for the gastroenterologist: history and potential CDR Murray, MA Kamm, SR Bloom, AV Emmanuel Gastroenterology 125 (5), 1492-1502, 2003 | 116 | 2003 |
| Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease GA Heap, K So, M Weedon, N Edney, C Bewshea, A Singh, V Annese, ... Journal of Crohn's and Colitis 10 (2), 149-158, 2016 | 114 | 2016 |
| Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial C Mowat, I Arnott, A Cahill, M Smith, T Ahmad, S Subramanian, S Travis, ... The lancet Gastroenterology & hepatology 1 (4), 273-282, 2016 | 110 | 2016 |
| UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care AJ Brooks, PJ Smith, R Cohen, P Collins, A Douds, V Forbes, DR Gaya, ... Gut 66 (6), 988-1000, 2017 | 109 | 2017 |
| Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis N Hansi, N Thoua, M Carulli, K Chakravarty, S Lal, A Smyth, A Herrick, ... Clin Exp Rheumatol 32 (6 Suppl 86), 214-21, 2014 | 101 | 2014 |
| Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis J Raja, SI Nihtyanova, CD Murray, CP Denton, VH Ong Rheumatology 55 (1), 115-119, 2016 | 87 | 2016 |
| Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised … L Peyrin-Biroulet, A Hart, P Bossuyt, M Long, M Allez, P Juillerat, ... The lancet Gastroenterology & hepatology 7 (2), 128-140, 2022 | 82 | 2022 |
| Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ... Nature communications 13 (1), 1379, 2022 | 73 | 2022 |
| Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study S Danese, JF Colombel, M Lukas, JP Gisbert, G d'Haens, B Hayee, ... The lancet Gastroenterology & hepatology 7 (2), 118-127, 2022 | 72 | 2022 |
| CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis AL Goodman, CD Murray, J Watkins, PD Griffiths, DP Webster European Journal of Clinical Microbiology & Infectious Diseases 34, 13-18, 2015 | 72 | 2015 |
Stuart A TaylorProfessor of Medical Imaging在 ucl.ac.uk 的电子邮件经过验证
Stuart A TaylorProfessor of Medical Imaging在 ucl.ac.uk 的电子邮件经过验证
Carel W Le RouxUniversity College Dublin在 ucd.ie 的电子邮件经过验证